Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
Regeneron(REGN) Newsfilter·2024-01-30 20:00Regeneron Cell Medicines成立 - Regeneron Pharmaceuticals, Inc.宣布成立Regeneron Cell Medicines，通过与2seventy bio, Inc.达成协议，获得其研究中的新型免疫细胞疗法管线的全面开发和商业化权利[1] - Regeneron将收购2seventy bio的前期和临床阶段管线，并承担与这些项目相关的持续程序、基础设施和人员成本[2] - Regeneron Cell Medicines将探索与Regeneron专有抗体和双特异性抗体的结合，推进下一代细胞疗法[3]